| 周莹艳.肿瘤型M2丙酮酸激酶在肺癌中的临床应用[J].浙江中西医结合杂志,2012,22(9):675-677 |
| 肿瘤型M2丙酮酸激酶在肺癌中的临床应用 |
| Clinical Significance of Plasma Tumor Type M2 Pyruvate Kinase Level in Patients with Lung Cancer |
| 投稿时间：2012-03-16 |
| DOI： |
| 中文关键词: 肺癌 肿瘤型M2 丙酮酸激酶 CEA NSE |
| 英文关键词:lung cancer tumor type M2 pyruvate kinase CEA NSE |
| 基金项目: |
|
| 摘要点击次数: 1100 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的： 观察肺癌患者血浆肿瘤型M2丙酮酸激酶 （TU M2-PK） 水平， 同时联合检测血CEA、
NSE以评价其对肺癌的诊断价值。方法： 采用酶联免疫吸附试验 （ELISA） 分别检测62例肺癌患者、
60例良性肺部疾病患者和45名健康体检者血浆TU M2-PK、 CEA、 NSE水平， 并进行比较分析。结
果： 肺癌组血浆TU M2-PK与良性肺疾病组和健康对照组比较， 差异有统计学意义 （P<0.05）； 随病
程进展肺癌患者TU M2-PK阳性率升高， 肺癌Ⅲ、 Ⅳ期患者TU M2-PK阳性率 （70.0%） 明显高于
Ⅰ、 Ⅱ期患者 （41.7%）（P<0.05）。单独检测TU M2-PK对肺癌的敏感性为64.5%， 特异性93.3%； 联
合CEA和NSE 检测时敏感性分别达到82.3%和74.2%， 特异性88.3%和91.7%。结论： TU M2-PK
对肺癌的辅助诊断有较高的临床价值， 与CEA、 NSE联合检测可提高肺癌诊断的敏感性。 |
| 英文摘要: |
| Objective： To investigate the role of tumor type M2 pyruvate kinase(M2-PK) in diagnosing patients
with lung cancer.Methods: Plasma tumor M2-PK （with ELISA） and CEA and NSE were determined in 62 lung
cancer patients and in 45 healthy subjects and 60 benign lung disease patients as controls. Results:The plasma
level of tumor M2-PK was significantly higher in lung cancer patients than that in benign lung disease and
healthy controls(P＜0.05)．The positive rate of tumor M2-PK in patients with stage Ⅲ or IV lung cancer
(70.0％)were higher than that in patients with stage I orⅡ(41.7％， P<0.05)．The diagnostic sensitivity and speci?
ficity of tumor M2-PK alone were 64.5％and 93.3%, respectively, which were 82.3％and 88.3% when combined
with CEA and 74.2% and 91.7% when combined with NSE, respectively．Conclusion: The measurement of tu?
mor M2-PK is of great clinical value for aided diagnosis of lung cancer．Combining tumor M2-PK and CEA
and NSE can improve diagnostic sensitivity. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
